Your browser doesn't support javascript.
loading
Sickle cell disease: embedding patient participation into an international conference can transform the role of lived experience.
Pellegrini, Mariangela; Chakravorty, Subarna; Del Mar Manu Pereira, Maria; Gulbis, Beatrice; Gilmour-Hamilton, Catriona; Hayes, Sandy; de Montalembert, Mariane; Inusa, Baba Psalm Duniya; Colombatti, Raffaella; Roy, Noémi Ba.
Affiliation
  • Pellegrini M; European Reference Network on Rare Hematological Disease, the ERN-EuroBloodNets, Hôpitaux de Paris, Hôpital Saint Louis, Paris, France. Mariangela.pellegrini@aphp.fr.
  • Chakravorty S; King's College Hospital NHS Foundation Trust, London, UK.
  • Del Mar Manu Pereira M; European Reference Network on Rare Hematological Diseases, the ERN-EuroBloodNet, Vall d'Hebron Research Institute/Vall d'Hebron University Hospital, Barcelona, Spain.
  • Gulbis B; European Reference Network on Rare Hematological Diseases, the ERN-EuroBloodNet, Hôpital Erasme/LHUB-ULB, Brussels, Belgium.
  • Gilmour-Hamilton C; Oxford University Hospitals NHS Trust, Oxford, England.
  • Hayes S; Oxford University Hospitals NHS Trust, Oxford, England.
  • de Montalembert M; European Reference Network On Rare Hematological Diseases, the ERN-EuroBloodNet, Hôpitaux de Paris, Hôpital Necker, Paris, France.
  • Inusa BPD; Paediatric Haematology, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Colombatti R; European Network of Rare Hematological Diseases, the ERN-EuroBloodNetPediatric Hematology Oncology Unit, Department of Women's and Child's Health, University of Padova, Padua, Italy.
  • Roy NB; Oxford University Hospitals NHS Trust, Oxford, England.
Orphanet J Rare Dis ; 18(1): 341, 2023 Nov 01.
Article in En | MEDLINE | ID: mdl-37908000
ABSTRACT

BACKGROUND:

Sickle cell disease (SCD) is an inherited chronic life-threatening disorder with increasing prevalence in Europe. People living with SCD in Europe mainly belong to vulnerable minorities, have a lower level of health education and suffer from isolation compared to those living with other chronic conditions. As a result, SCD patients are much less likely to partner in the design of research related to their condition and are limited in their ability to influence the research agenda. Aiming to increase the influence of patient voice in the development of SCD-related research, we set out to develop patient centered actions in the frame of International Scientific Conferences in collaboration with the ERN-EuroBloodNet, Oxford Blood Group, Annual Sickle Cell Disease and Thalassaemia Conference (ASCAT), the European Hematology Association and the British Society of Hematology.

RESULTS:

Two events were organized a one-day research prioritization workshop and a series of education sessions based on topics chosen by SCD patients and their families. Methodology and outcomes were analyzed in terms of influence on scientific, medical and patient communities.

CONCLUSION:

The ERN-EuroBloodNet workshops with patients at annual ASCAT conferences have provided an opportunity to enhance patient experience and empowerment in SCD in Europe, producing benefits for patients, caregivers, patient associations and health professionals. Future work should focus on delivering the research questions identified at this workshop and the opportunities to share information for patient education.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Patient Participation / Anemia, Sickle Cell Limits: Humans Country/Region as subject: Europa Language: En Journal: Orphanet J Rare Dis Journal subject: MEDICINA Year: 2023 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Patient Participation / Anemia, Sickle Cell Limits: Humans Country/Region as subject: Europa Language: En Journal: Orphanet J Rare Dis Journal subject: MEDICINA Year: 2023 Document type: Article Affiliation country: France
...